| scholarly article | Q13442814 |
| P50 | author | Terence S. Dermody | Q87776424 |
| P2093 | author name string | Laurie A Silva | |
| P2860 | cites work | Emerging arboviruses in the Pacific. | Q51840163 |
| Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus | Q21090106 | ||
| Characterization of reemerging chikungunya virus | Q21090531 | ||
| A single mutation in chikungunya virus affects vector specificity and epidemic potential | Q21131599 | ||
| Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak | Q21144706 | ||
| Predictors of Chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study | Q21195256 | ||
| Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? | Q21245126 | ||
| Discovery of frameshifting in Alphavirus 6K resolves a 20-year enigma | Q21245130 | ||
| Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism | Q21559402 | ||
| A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease | Q21559504 | ||
| Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study | Q21562246 | ||
| Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period | Q21562272 | ||
| Human muscle satellite cells as targets of Chikungunya virus infection | Q21562321 | ||
| Zika virus: following the path of dengue and chikungunya? | Q22330711 | ||
| Concurrent outbreaks of dengue, chikungunya and Zika virus infections – an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014 | Q22330735 | ||
| Sylvatic transmission of arboviruses among Bornean orangutans | Q22330807 | ||
| The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus | Q22680660 | ||
| Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate | Q24276430 | ||
| Emergence and potential for spread of Chikungunya virus in Brazil | Q24288877 | ||
| Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages | Q24288996 | ||
| Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response | Q34110965 | ||
| Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia | Q34222718 | ||
| An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952–1953 II. General description and epidemiology | Q34261544 | ||
| Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein | Q34264257 | ||
| Arthritogenic alphaviruses--an overview | Q34273343 | ||
| Venereal transmission of chikungunya virus by Aedes aegypti mosquitoes (Diptera: Culicidae) | Q34341802 | ||
| Seroprevalence survey of Chikungunya virus in Bagan Panchor, Malaysia | Q34341808 | ||
| Comparative pathogenesis of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque model | Q34341822 | ||
| Chikungunya and dengue: A Case of Mistaken Identity? | Q24471144 | ||
| Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships | Q24570057 | ||
| Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal | Q24575550 | ||
| Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock | Q24598171 | ||
| Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor | Q24625887 | ||
| Chikungunya infection in travelers | Q24628887 | ||
| A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection | Q24631774 | ||
| Type I IFN controls chikungunya virus via its action on nonhematopoietic cells | Q24647231 | ||
| Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology | Q24701757 | ||
| Expanding Regulatory T Cells Alleviates Chikungunya Virus-Induced Pathology in Mice | Q24701758 | ||
| Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane Fusion | Q24701760 | ||
| Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice | Q24701776 | ||
| Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes | Q24701786 | ||
| Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection | Q24701792 | ||
| CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis | Q24701793 | ||
| Macrophages in rheumatoid arthritis | Q24806949 | ||
| Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses | Q26314623 | ||
| γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease | Q26314703 | ||
| Chikungunya vaccines in development | Q26700081 | ||
| A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis | Q26700129 | ||
| Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model) | Q26782722 | ||
| Reappearance of chikungunya, formerly called dengue, in the Americas | Q26849542 | ||
| Chikungunya fever: a clinical and virological investigation of outpatients on Reunion Island, South-West Indian Ocean | Q27305283 | ||
| Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus | Q27335008 | ||
| Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells | Q27468832 | ||
| The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic | Q27469278 | ||
| Biogenesis of the Semliki Forest virus RNA replication complex | Q27469902 | ||
| The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process | Q27478445 | ||
| Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion | Q27485485 | ||
| Site-directed mutations in the Sindbis virus E2 glycoprotein identify palmitoylation sites and affect virus budding | Q27486025 | ||
| Chikungunya Fever in Travelers Returning to Europe from the Indian Ocean Region, 2006 | Q27487088 | ||
| Chimeric alphavirus vaccine candidates for chikungunya | Q27487105 | ||
| IL-1β, IL-6, and RANTES as Biomarkers of Chikungunya Severity | Q27487567 | ||
| Epistatic Roles of E2 Glycoprotein Mutations in Adaption of Chikungunya Virus to Aedes Albopictus and Ae. Aegypti Mosquitoes | Q27489379 | ||
| Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response | Q34378105 | ||
| Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus | Q34391631 | ||
| Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice | Q34394530 | ||
| A phenotypic assay to identify Chikungunya virus inhibitors targeting the nonstructural protein nsP2. | Q34415623 | ||
| Evolutionary influences in arboviral disease | Q34506254 | ||
| Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression | Q34527618 | ||
| Dissemination and transmission of the E1-226V variant of chikungunya virus in Aedes albopictus are controlled at the midgut barrier level | Q34600603 | ||
| Effective chikungunya virus-like particle vaccine produced in insect cells | Q34630576 | ||
| Towards antivirals against chikungunya virus | Q34670977 | ||
| A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence | Q34756658 | ||
| Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients | Q34875480 | ||
| Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity | Q34927480 | ||
| Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes | Q34977748 | ||
| Aedes furcifer and other mosquitoes as vectors of chikungunya virus at Mica, northeastern Transvaal, South Africa | Q35004989 | ||
| Genome-wide RNAi screen identifies novel host proteins required for alphavirus entry | Q35075132 | ||
| Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design | Q35109218 | ||
| Case reports of neuro-Chikungunya in southern Thailand | Q35131464 | ||
| Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. | Q35168183 | ||
| Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response | Q35192818 | ||
| Chikungunya virus: evolution and genetic determinants of emergence | Q35240173 | ||
| A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection | Q35641902 | ||
| The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation | Q35838581 | ||
| Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus | Q35850197 | ||
| Chikungunya virus, southeastern France | Q35876743 | ||
| Chikungunya virus-induced autophagy delays caspase-dependent cell death | Q35946144 | ||
| Versatile Trans-Replication Systems for Chikungunya Virus Allow Functional Analysis and Tagging of Every Replicase Protein | Q35952215 | ||
| A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design | Q36171996 | ||
| Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. | Q36200552 | ||
| Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus | Q36303514 | ||
| Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress | Q36318652 | ||
| Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development | Q36397446 | ||
| Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis | Q36483436 | ||
| Effects of an In-Frame Deletion of the 6k Gene Locus from the Genome of Ross River Virus | Q36736422 | ||
| Interspecies transmission and chikungunya virus emergence | Q36777365 | ||
| An essential role of antibodies in the control of Chikungunya virus infection | Q36914762 | ||
| Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage | Q36922074 | ||
| Chikungunya virus with E1-A226V mutation causing two outbreaks in 2010, Guangdong, China | Q36953012 | ||
| Functional characterization of the alphavirus TF protein | Q37036697 | ||
| Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence | Q37214518 | ||
| Chikungunya fever outbreak, Bhutan, 2012 | Q37261986 | ||
| Outbreak of chikungunya virus infection, Vanimo, Papua New Guinea | Q37262372 | ||
| Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein | Q37383882 | ||
| Chikungunya fever: an epidemiological review of a re-emerging infectious disease | Q37575480 | ||
| Atypical manifestations of chikungunya infection | Q37588903 | ||
| Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus | Q37660700 | ||
| Biology and pathogenesis of chikungunya virus | Q37765475 | ||
| Chikungunya fever in the United States: a fifteen year review of cases | Q37829554 | ||
| Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology | Q37993737 | ||
| Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy | Q38118022 | ||
| A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization | Q38329445 | ||
| Chikungunya triggers an autophagic process which promotes viral replication | Q38560348 | ||
| Protective and Pathogenic Responses to Chikungunya Virus Infection | Q38586243 | ||
| Design and Validation of Novel Chikungunya Virus Protease Inhibitors | Q38735142 | ||
| Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization. | Q38838063 | ||
| Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus | Q38895828 | ||
| How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America? | Q38999094 | ||
| Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site | Q39132098 | ||
| Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice | Q39172123 | ||
| Multi-peaked adaptive landscape for chikungunya virus evolution predicts continued fitness optimization in Aedes albopictus mosquitoes | Q39175323 | ||
| Alphaviruses in Peninsular Malaysia: II. Serological evidence of human infection | Q39366401 | ||
| Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial | Q39382188 | ||
| pH-dependent entry of chikungunya virus into Aedes albopictus cells | Q39386501 | ||
| Chikungunya virus of Asian and Central/East African genotypes in Malaysia | Q39426290 | ||
| Differential proteome analysis of Chikungunya virus-infected new-born mice tissues reveal implication of stress, inflammatory and apoptotic pathways in disease pathogenesis | Q39562528 | ||
| Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses | Q39649864 | ||
| Functional Sindbis virus replicative complexes are formed at the plasma membrane | Q39657845 | ||
| Interactions between the transmembrane segments of the alphavirus E1 and E2 proteins play a role in virus budding and fusion | Q39732657 | ||
| Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response | Q39881534 | ||
| Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography | Q27666147 | ||
| The alphaviruses: gene expression, replication, and evolution | Q27860954 | ||
| Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity | Q28476579 | ||
| A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease | Q28533408 | ||
| Heat shock protein 90 positively regulates Chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection | Q28539964 | ||
| Loss of Glycosaminoglycan Receptor Binding after Mosquito Cell Passage Reduces Chikungunya Virus Infectivity | Q28550385 | ||
| Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection | Q28828878 | ||
| Infection with chikungunya virus in Italy: an outbreak in a temperate region | Q29346487 | ||
| Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus | Q29620003 | ||
| An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features | Q29620004 | ||
| Stress granule components G3BP1 and G3BP2 play a proviral role early in Chikungunya virus replication | Q30009234 | ||
| US Military contributions to the global response to pandemic chikungunya | Q30224145 | ||
| Phosphatidylinositol 3-kinase-, actin-, and microtubule-dependent transport of Semliki Forest Virus replication complexes from the plasma membrane to modified lysosomes | Q30495294 | ||
| Structural evidence of glycoprotein assembly in cellular membrane compartments prior to Alphavirus budding | Q30496938 | ||
| Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein | Q30516488 | ||
| Vectors of Chikungunya virus in Senegal: current data and transmission cycles | Q30559453 | ||
| Identification of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as novel inhibitors of Chikungunya virus replication | Q30814936 | ||
| Random codon re-encoding induces stable reduction of replicative fitness of Chikungunya virus in primate and mosquito cells | Q31111619 | ||
| Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients | Q33375141 | ||
| Clinical features and epidemiology of chikungunya infection in Singapore | Q33386006 | ||
| Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies | Q33517926 | ||
| Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments | Q33632225 | ||
| Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. | Q33684369 | ||
| Perceived morbidity and community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study | Q33793512 | ||
| Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency | Q33806890 | ||
| Neurocognitive outcome of children exposed to perinatal mother-to-child Chikungunya virus infection: the CHIMERE cohort study on Reunion Island | Q33916134 | ||
| Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. | Q33942533 | ||
| Distribution of three arbovirus antibodies among monkeys (Macaca fascicularis) in the Philippines | Q33966743 | ||
| Evidence of experimental vertical transmission of emerging novel ECSA genotype of Chikungunya Virus in Aedes aegypti | Q33981774 | ||
| Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates | Q33990566 | ||
| Ribavirin therapy for Chikungunya arthritis. | Q34019291 | ||
| Species-specific impact of the autophagy machinery on Chikungunya virus infection | Q34036496 | ||
| Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity | Q34037685 | ||
| Replication cycle of chikungunya: a re-emerging arbovirus | Q34042046 | ||
| Chikungunya virus arthritis in adult wild-type mice | Q34046030 | ||
| Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus | Q40077669 | ||
| A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes | Q40082746 | ||
| Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. | Q40210836 | ||
| Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits | Q40232449 | ||
| A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus | Q40245153 | ||
| Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region). | Q40267431 | ||
| Impaired quality of life after chikungunya virus infection: a 2-year follow-up study | Q40292985 | ||
| A fatal case of chikungunya virus infection with liver involvement. | Q40336232 | ||
| Re-emergence of Chikungunya virus in South-east Asia: virological evidence from Sri Lanka and Singapore | Q40372568 | ||
| Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion | Q40412307 | ||
| A226V mutation in virus during the 2007 chikungunya outbreak in Kerala, India. | Q40414131 | ||
| Effects of site-directed mutations of transmembrane cysteines in sindbis virus E1 and E2 glycoproteins on palmitylation and virus replication | Q41008365 | ||
| Fate of the 6K membrane protein of Semliki Forest virus during virus assembly | Q41653530 | ||
| Molecular mechanisms involved in the pathogenesis of alphavirus-induced arthritis | Q41857816 | ||
| Chikungunya virus aches and pains: an emerging challenge | Q41940293 | ||
| Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial | Q42199381 | ||
| Chikungunya Virus in Macaques, Malaysia | Q42539696 | ||
| Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic | Q42623122 | ||
| Chikungunya virus infection, Brazzaville, Republic of Congo, 2011. | Q42930994 | ||
| FURTHER STUDIES ON THE CHIKUNGUNYA OUTBREAK IN SOUTHERN RHODESIA IN 1962. I. MOSQUITOES, WILD PRIMATES AND BIRDS IN RELATION TO THE EPIDEMIC. | Q42979179 | ||
| Experimental infection of Macaca radiata with Chikungunya virus and transmission of virus by mosquitoes | Q42998346 | ||
| Laboratory vector studies on six mosquito and one tick species with chikungunya virus | Q43001737 | ||
| Chikungunya-related fatality rates, Mauritius, India, and Reunion Island | Q43230235 | ||
| Development of an attenuated strain of chikungunya virus for use in vaccine production | Q44523303 | ||
| The Sindbis virus 6K protein can be detected in virions and is acylated with fatty acids | Q44673795 | ||
| The burden of chikungunya in the Pacific | Q44847469 | ||
| Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. | Q44849755 | ||
| Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. | Q44850657 | ||
| Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island | Q44851009 | ||
| An animal model for studying the pathogenesis of chikungunya virus infection | Q44851012 | ||
| Molecular and serological diagnosis of Chikungunya virus infection | Q44851228 | ||
| Immunologic interference from sequential administration of live attenuated alphavirus vaccines. | Q44851631 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Chikungunya virus | Q15794049 |
| chikungunya | Q243257 | ||
| P304 | page(s) | 737-749 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies | |
| P478 | volume | 127 |
| Q40070488 | 18F-FDG PET/CT Findings in a Patient with Chikungunya Virus Infection. |
| Q52309592 | A Chikungunya virus trans-replicase system reveals the importance of delayed non-structural polyprotein processing for efficient replication complex formation in mosquito cells. |
| Q92668013 | A Factor I-Like Activity Associated with Chikungunya Virus Contributes to Its Resistance to the Human Complement System |
| Q101452757 | A critical role for STING signaling in limiting pathogenesis of Chikungunya virus |
| Q100940164 | A molecular understanding of alphavirus entry |
| Q57091720 | A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control |
| Q60310690 | Adult immunization – Need of the hour |
| Q90186487 | Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis |
| Q90741933 | Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate |
| Q89650120 | Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus |
| Q95943125 | Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis |
| Q92959636 | Brief report: the disability of chronic chikungunya arthritis |
| Q101223354 | CXCL10 Signaling Contributes to the Pathogenesis of Arthritogenic Alphaviruses |
| Q58575620 | Cellular and Molecular Immune Response to Chikungunya Virus Infection |
| Q91675144 | Chandipura Virus Utilizes the Prosurvival Function of RelA NF-κB for Its Propagation |
| Q41923135 | Chikungunya Virus-Associated Disease |
| Q92167958 | Chikungunya Virus: A Back-Breaking Problem |
| Q89626909 | Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle |
| Q100394710 | Chikungunya virus strains from each genetic clade bind sulfated glycosaminoglycans as attachment factors |
| Q110770998 | Climatic and socio-economic factors supporting the co-circulation of dengue, Zika and chikungunya in three different ecosystems in Colombia |
| Q100510173 | Clinical features and laboratory diagnosis of emerging arthropod-transmitted viruses: A Report from the Pan American Society for Clinical Virology Clinical Practice Committee |
| Q104757295 | Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease |
| Q94561515 | Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections |
| Q104690772 | Current and Promising Antivirals Against Chikungunya Virus |
| Q104800078 | Deciphering the human cellular interactors of alphavirus unique domain of Chikungunya Virus |
| Q59350720 | Defining a correlate of protection for chikungunya virus vaccines |
| Q90833743 | Demographic and clinical characteristics of chikungunya patients from six Colombian cities, 2014-2015 |
| Q62485361 | Discovery and Characterization of 2-Nitro-5-(4-(phenylsulfonyl)piperazin-1-yl)- N-(pyridin-4-ylmethyl)anilines as Novel Inhibitors of the Aedes aegypti Kir1 ( AeKir1) Channel |
| Q94538384 | Discovery of Widespread Host Protein Interactions with the Pre-replicated Genome of CHIKV Using VIR-CLASP |
| Q66678852 | Distinguishing patients with laboratory-confirmed chikungunya from dengue and other acute febrile illnesses, Puerto Rico, 2012-2015 |
| Q110771171 | Ebola, Dengue, Chikungunya, and Zika Infections in Neonates and Infants |
| Q95827620 | Epidemiologic Characteristics of Imported and Domestic Chikungunya Cases in Taiwan: A 13-Year Retrospective Study |
| Q59350373 | Epidemiological Evidence for Lineage-specific Differences in the Risk of Inapparent Chikungunya Virus Infection |
| Q90289089 | FHL1 is a major host factor for chikungunya virus infection |
| Q90865855 | Genetic and Phylogenetic Characterization of a Chikungunya Virus Imported into Shenzhen, China |
| Q96766177 | Genetic polymorphisms in DC-SIGN, TLR3 and TNFa genes and the Lewis-negative phenotype are associated with Chikungunya infection and disease in Nicaragua |
| Q96645872 | Genomic surveillance of the Chikungunya Virus (CHIKV) in Northeast Brazil after the first outbreak in 2014 |
| Q47557749 | How Do Virus-Mosquito Interactions Lead to Viral Emergence? |
| Q101126904 | Inhibition of transient receptor potential vanilloid 1 (TRPV1) channel regulates chikungunya virus infection in macrophages |
| Q97675859 | Interepidemic Detection of Chikungunya Virus Infection and Transmission in Northeastern Thailand |
| Q104282759 | Interleukin-17A Facilitates Chikungunya Virus Infection by Inhibiting IFN-α2 Expression |
| Q98296991 | JNK pathway restricts DENV2, ZIKV and CHIKV infection by activating complement and apoptosis in mosquito salivary glands |
| Q47242810 | Lower temperatures reduce type I interferon activity and promote alphaviral arthritis |
| Q100504004 | Macrophage scavenger receptor 1 controls Chikungunya virus infection through autophagy in mice |
| Q100493445 | Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections |
| Q112069069 | Molecular Epidemiology, Evolution and Reemergence of Chikungunya Virus in South Asia |
| Q102380956 | Molecular characterization and phylogenetic analysis of Chikungunya virus during the 2016 outbreak in Sergipe, northeastern Brazil |
| Q56958245 | Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis |
| Q58098885 | Neuromodulation treats Chikungunya arthralgia: a randomized controlled trial |
| Q97535794 | Perinatal Vertical Transmission of Chikungunya Virus in Ruili, a Town on the Border between China and Burma |
| Q44843482 | Recent progress on chikungunya virus research. |
| Q97590358 | Revisiting an old friend: new findings in alphavirus structure and assembly |
| Q93087252 | Rheumatic manifestations of chikungunya: emerging concepts and interventions |
| Q40043045 | Septic Shock Secondary to Chikungunya Virus in a 3-Month-Old Traveler Returning From Honduras |
| Q93161987 | Serotonergic drugs inhibit CHIKV infection at different stages of the cell entry pathway |
| Q58099570 | Silvestrol Inhibits Chikungunya Virus Replication |
| Q90460751 | Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection |
| Q66679599 | Systems analysis of subjects acutely infected with the Chikungunya virus |
| Q92497497 | Targeting Chikungunya virus by computational approaches: from viral biology to the development of therapeutic strategies |
| Q54268571 | The Alphavirus Exit Pathway: What We Know and What We Wish We Knew. |
| Q56988192 | The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies |
| Q100991821 | The Role of Temperature in Shaping Mosquito-Borne Viruses Transmission |
| Q57826353 | The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines |
| Q92866471 | The effects of climate change on human health in Africa, a dermatologic perspective: a report from the International Society of Dermatology Climate Change Committee |
| Q54232538 | The neurological complications of chikungunya virus: A systematic review. |
| Q110771000 | The worldwide seroprevalence of DENV, CHIKV and ZIKV infection: A systematic review and meta-analysis |
| Q62737885 | Tropism of the Chikungunya Virus |
| Q108757688 | Viral and Prion Infections Associated with Central Nervous System Syndromes in Brazil |
| Q100465257 | Viral and host heterogeneity and their effects on the viral life cycle |
| Q91147075 | Viromics Reveal a Number of Novel RNA Viruses in Swedish Mosquitoes |
| Q91324976 | Zika Virus Dissemination from the Midgut of Aedes aegypti is Facilitated by Bloodmeal-Mediated Structural Modification of the Midgut Basal Lamina |
| Q38156532 | Zika, Chikungunya, and Other Emerging Vector-Borne Viral Diseases |
| Q93217821 | [Chronic chikungunya arthritis] |
| Q98160010 | [Methodological quality assessment of guidelines for surveillance and clinical management of dengue and chikungunya] |
Search more.